These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26543378)

  • 1. Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells.
    Liu X; Sun M; Yu S; Liu K; Li X; Shi H
    Onco Targets Ther; 2015; 8():3095-104. PubMed ID: 26543378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
    Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
    Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.
    Barber A; Zhang T; Megli CJ; Wu J; Meehan KR; Sentman CL
    Exp Hematol; 2008 Oct; 36(10):1318-28. PubMed ID: 18599182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.
    Lehner M; Götz G; Proff J; Schaft N; Dörrie J; Full F; Ensser A; Muller YA; Cerwenka A; Abken H; Parolini O; Ambros PF; Kovar H; Holter W
    PLoS One; 2012; 7(2):e31210. PubMed ID: 22355347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
    Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
    Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
    Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.
    Barber A; Meehan KR; Sentman CL
    Gene Ther; 2011 May; 18(5):509-16. PubMed ID: 21209626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
    Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
    Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
    Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
    Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
    Bilotta MT; Abruzzese MP; Molfetta R; Scarno G; Fionda C; Zingoni A; Soriani A; Garofalo T; Petrucci MT; Ricciardi MR; Paolini R; Santoni A; Cippitelli M
    FASEB J; 2019 Aug; 33(8):9489-9504. PubMed ID: 31125275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomy.
    Kamei R; Yoshimura K; Yoshino S; Inoue M; Asao T; Fuse M; Wada S; Kuramasu A; Furuya-Kondo T; Oga A; Iizuka N; Suzuki N; Maeda N; Watanabe Y; Matsukuma S; Iida M; Takeda S; Ueno T; Yamamoto N; Fukagawa T; Katai H; Sasaki H; Hazama S; Oka M; Nagano H
    Oncol Lett; 2018 Jan; 15(1):747-754. PubMed ID: 29391893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
    Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
    Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
    VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
    Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2007 Nov; 67(22):11029-36. PubMed ID: 18006849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
    Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
    Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.
    Shiraishi K; Mimura K; Kua LF; Koh V; Siang LK; Nakajima S; Fujii H; Shabbir A; Yong WP; So J; Takenoshita S; Kono K
    J Gastroenterol; 2016 Dec; 51(12):1101-1111. PubMed ID: 27002316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.
    Kato N; Tanaka J; Sugita J; Toubai T; Miura Y; Ibata M; Syono Y; Ota S; Kondo T; Asaka M; Imamura M
    Leukemia; 2007 Oct; 21(10):2103-8. PubMed ID: 17625602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.